<DOC>
	<DOCNO>NCT02603302</DOCNO>
	<brief_summary>This one arm study patient locally advanced rectal cancer receive neoadjuvant treatment escalate dose radiotherapy ( 3D conformal radiotherapy , 59,4 Gy ) radiosensitizing chemotherapy . Then , patient operate ( total mesorectal excision ) 8 week interval . Primary endpoint pCR ( pathologic complete response ) .</brief_summary>
	<brief_title>Radiation Dose Escalation Locally Advanced Rectal Cancer</brief_title>
	<detailed_description>Introduction : Rectal cancer highly prevalent disease world . In Brazil , second common cancer among woman ( breast tumor ) , estimate incidence 17.2 case per 100,000 inhabitant third common cancer men ( prostate lung cancer ) , estimate incidence 15.4 case per 100,000 inhabitant . Goals : The aim study evaluate pathologic complete response ( pCR ) patient locally advanced rectal cancer ( LARC ) treat neoadjuvant radiochemotherapy ( RCT ) employ anticancer drug standard dose interval extend surgery without adjuvant neoplastic therapy . Procedures : Neoadjuvant chemoradiotherapy radiation dose escalation associate radiosensitizing therapy surgery total mesorectal excision ( TME ) , 8 week complete neoadjuvant treatment .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>Locally advanced rectal cancer , 015 cm anal verge , cT3/4 cN+ Metastatic disease , previous chemotherapy , previous radiotherapy , previous malignant nonskin tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>rectal cancer</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>escalate dose</keyword>
	<keyword>interval</keyword>
</DOC>